Inulin Improves Postprandial Hypertriglyceridemia by Modulating Gene Expression in the Small Intestine

Nutrients. 2018 Apr 25;10(5):532. doi: 10.3390/nu10050532.

Abstract

Postprandial hyperlipidemia is an important risk factor for cardiovascular diseases in the context of obesity. Inulin is a non-digestible carbohydrate, known for its beneficial properties in metabolic disorders. We investigated the impact of inulin on postprandial hypertriglyceridemia and on lipid metabolism in a mouse model of diet-induced obesity. Mice received a control or a western diet for 4 weeks and were further supplemented or not with inulin for 2 weeks (0.2 g/day per mouse). We performed a lipid tolerance test, measured mRNA expression of genes involved in postprandial lipid metabolism, assessed post-heparin plasma and muscle lipoprotein lipase activity and measured lipid accumulation in the enterocytes and fecal lipid excretion. Inulin supplementation in western diet-fed mice decreases postprandial serum triglycerides concentration, decreases the mRNA expression levels of Cd36 (fatty acid receptor involved in lipid uptake and sensing) and apolipoprotein C3 (Apoc3, inhibitor of lipoprotein lipase) in the jejunum and increases fecal lipid excretion. In conclusion, inulin improves postprandial hypertriglyceridemia by targeting intestinal lipid metabolism. This work confirms the interest of using inulin supplementation in the management of dyslipidemia linked to obesity and cardiometabolic risk.

Keywords: inulin; obesity; postprandial hypertriglyceridemia.

MeSH terms

  • Animals
  • Apolipoprotein C-III / genetics
  • Apolipoprotein C-III / metabolism
  • Biomarkers / blood
  • CD36 Antigens / genetics
  • CD36 Antigens / metabolism
  • Disease Models, Animal
  • Gene Expression Regulation
  • Hypertriglyceridemia / blood
  • Hypertriglyceridemia / drug therapy*
  • Hypertriglyceridemia / genetics
  • Hypolipidemic Agents / pharmacology*
  • Intestine, Small / drug effects*
  • Intestine, Small / metabolism
  • Inulin / pharmacology*
  • Lipid Metabolism / drug effects*
  • Lipid Metabolism / genetics
  • Male
  • Mice, Inbred C57BL
  • Obesity / blood
  • Obesity / drug therapy*
  • Obesity / genetics
  • Postprandial Period*
  • RNA, Messenger / genetics
  • RNA, Messenger / metabolism
  • Time Factors
  • Triglycerides / blood*

Substances

  • Apolipoprotein C-III
  • Biomarkers
  • CD36 Antigens
  • Hypolipidemic Agents
  • RNA, Messenger
  • Triglycerides
  • Inulin